-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Downgrades Health Catalyst to Hold, Lowers Price Target to $1.8

Benzinga·08/21/2026 12:42:26
Listen to the news
Canaccord Genuity analyst Richard Close downgrades Health Catalyst (NASDAQ:HCAT) from Buy to Hold and lowers the price target from $3 to $1.8.